B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

B of A Securities analyst Tazeen Ahmad has maintained a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ: FDMT) and increased the price target from $29 to $33. This adjustment reflects a positive outlook for the company's stock performance.